NCT01697319 - Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

Mucopolysaccharidosis IVAMorquio A SyndromeMPS IVA

Interventions

DRUG

BMN 110

Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.

Trial Locations (7)

Children's Hospital & Research Center Oakland, Oakland

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

Universitätsklinikum Hamburg, Hamburg

University Medical Center Mainz, Center of Pediatric and Adolescent Medicine Villa Metabolica, Mainz

NIHR/Wellcome Trust Birmingham CRF, Queen Elizabeth Hospital, Birmingham

Central Manchester University Hospitals NHS Foundation Trust, Manchester

Salford Royal NHS Foundation Trust, Salford